Darlene Noci brings to Nuvalent over 20 years of experience as an accomplished global product development leader specializing in global regulatory affairs and strategic oversight of early and late-stage programs.
Throughout her career, Darlene contributed to several successful drug approvals, including Fabrazyme®, Mozobil®, Clolar®/Evoltra®, and Bavencio®. Prior to founding her own regulatory consulting firm in 2018, Darlene served as Vice President, Regulatory Affairs and Quality Assurance at X4 Pharmaceuticals. Prior to X4, Darlene served as Global Regulatory Lead Strategist, Immuno-Oncology at EMD Serono, the North America biopharma business of Merck KgaA, Darmstadt, Germany where she led the global regulatory strategy and portfolio for Bavencio®, the company’s anti-programmed death-ligand 1 (PDL-1) antibody. In this role, she was instrumental in the global clinical development to a proof of concept spanning more than 10 solid tumor indications, including non-small cell lung cancer and urothelial carcinoma. Darlene drove the team responsible for securing Bavencio’s Orphan Drug Designation, Fast Track Designation, and Breakthrough Therapy Designation, which led to accelerated approval for the treatment of patients with Merkel Cell Carcinoma. Darlene also served on the joint steering committee with Pfizer. Prior to EMD Serono, she held various regulatory and team leadership positions with increasing responsibility in oncology and rare disease at several companies including Infinity, Sanofi, and Genzyme. She gives credit to her mentors at Genzyme, where she spent 14 years, inspired by leaders driven by science and passion for bringing much needed therapies to patients.
Darlene earned her Master’s degree in Government from Harvard University.
What is Darlene Noci's net worth?
The estimated net worth of Darlene Noci is at least $2.80 million as of October 1st, 2024. Ms. Noci owns 33,300 shares of Nuvalent stock worth more than $2,804,526 as of December 21st. This net worth approximation does not reflect any other investments that Ms. Noci may own. Learn More about Darlene Noci's net worth.
How old is Darlene Noci?
Ms. Noci is currently 46 years old. There are 5 older executives and no younger executives at Nuvalent. The oldest executive at Nuvalent is Prof. Matthew D. Shair Ph.D., Founder, Head of Scientific Advisory Board & Director, who is 55 years old. Learn More on Darlene Noci's age.
How do I contact Darlene Noci?
Has Darlene Noci been buying or selling shares of Nuvalent?
In the last ninety days, Darlene Noci has sold $508,700.00 in shares of Nuvalent stock. Most recently, Darlene Noci sold 5,000 shares of the business's stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $101.74, for a transaction totalling $508,700.00. Following the completion of the sale, the insider now directly owns 33,300 shares of the company's stock, valued at $3,387,942. Learn More on Darlene Noci's trading history.
Who are Nuvalent's active insiders?
Are insiders buying or selling shares of Nuvalent?
During the last year, insiders at the sold shares 43 times. They sold a total of 3,520,279 shares worth more than $309,132,982.40. The most recent insider tranaction occured on December, 16th when CEO James Richard Porter sold 27,000 shares worth more than $2,338,470.00. Insiders at Nuvalent own 12.5% of the company.
Learn More about insider trades at Nuvalent. Information on this page was last updated on 12/16/2024.
